

Table 2 Adverse Events among subgroups by different dose.																	
Cohort		1×10 <sup>4</sup> (±30%)/kg				Phase Ia 5×10 <sup>4</sup> (±30%)/kg				1×10 <sup>5</sup> (±30%)/kg				Phas 1×10 <sup>5</sup> (±30%)/kg			
AEs within day30		N=40															
Grade		1-2	3	4	5	1-2	3	4	5	1-2	3	4	5	1-2	3	4	5
CRS																	
Total score		2	0	0	0	3	0	0	0	2	0	0	0	28	2	0	0
Fever (≥38°C)		3	0	0	0	3	0	0	0	2	0	0	0	12	13	0	0
Hypotension		0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
Hypoxia		0	0	0	0	0	0	0	0	0	0	0	0	4	0	0	0
ICANS																	
Total score		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0
Depressed consciousness		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Seizure		0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0
Motor weakness		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Elevated ICP or cerebra		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
GVHD*																	
Total score		0	0	0	0	0	0	0	0	0	0	0	0	4	0	0	0
Skin		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Liver		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Intestinal		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Hematologic event																	
Neutropenia		1	0	2	0	0	0	3	0	0	0	3	0	0	1	30	0
Leukopenia		1	0	2	0	0	0	3	0	0	0	3	0	0	1	30	0
Thrombocytopenia		1	0	2	0	0	0	3	0	1	0	2	0	4	5	18	0
Anemia		1	2	0	0	0	3	0	0	0	3	0	0	6	5	20	0
Lymphocytopenia		1	0	2	0	0	0	3	0	0	0	3	0	0	1	30	0
Infections																	
Sepsis		0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Intestinal infection		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Lung infection		0	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0
Skin infection		0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0
Oral ulcer		1	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0
Infection pathogen																	
Virus		0	1	0	0	0	0	0	0	0	0	0	0	2	2	0	0
Bacteria		0	1	0	0	1	1	0	0	0	0	0	0	1	2	0	0
Fungus		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gastrointestinal event																	
Abdominal distension		1	1	0	0	1	0	0	0	1	0	0	0	3	8	6	0
Loss of appetite		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Nausea/Vomiting		0	0	0	0	1	0	0	0	1	0	0	0	3	2	0	0
Diarrhea		1	0	0	0	0	0	0	0	0	0	0	0	8	0	0	0
Cardiovascular event																	
Chest pain		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tachycardia		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Heart failure		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
General conditions																	
Fatigue		1	0	0	0	1	0	0	0	1	0	0	0	5	0	0	0
Flu-like symptom		0	0	0	0	0	0	0	0	1	0	0	0	3	0	0	0
Rash		1	0	0	0	1	0	0	0	0	0	0	0	9	0	0	0
Peripheral edema		0	0	0	0	0	0	0	0	1	0	0	0	3	0	0	0
IEC-HS		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Capillary leak syndrome		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Laboratory values																	
AST increase		1	0	0	0	2	0	0	0	1	1	0	0	3	0	0	0
ALT increase		1	1	0	0	0	0	0	0	1	0	0	0	6	1	0	0
Bilirubin increase		1	0	0	0	0	0	0	0	1	0	0	0	3	0	0	0
Creatine increase		0	0	0	0	1	0	0	0	0	0	0	0	4	0	0	0
LDH increase		1	0	0	0	0	0	0	0	2	0	0	0	8	0	0	0
Coagulopathy		1	0	0	0	1	0	0	0	1	0	0	0	20	0	0	0
Hypoalbuminemia		0	1	0	0	2	0	0	0	2	0	0	0	7	1	0	0
Hypocalcemia		0	1	0	0	0	0	0	0	0	0	0	0	4	2	0	0
Hypokalemia		1	1	0	0	2	0	0	0	2	0	0	0	7	2	0	0
Hyponatremia		0	1	0	0	1	0	0	0	1	0	0	0	9	0	0	0
AEs after day30**		N=37															
Grade		1-2	3	4	5	1-2	3	4	5	1-2	3	4	5	1-2	3	4	5
Acute GVHD*																	
Total score		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Skin		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liver		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intestinal		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic GVHD*																	
Extensive cGVHD		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Limited cGVHD		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Infections																	
Virus		0	0	0	1	0	0	0	1	0	0	0	0	3	4	0	0
Bacteria		0	0	0	0	0	0	0	0	0	0	0	0	2	3	0	4
Fungus		0	0	1	0	0	0	0	0	0	0	0	0	5	1	0	1
Secondary neoplasm		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Listed are all adverse events, which occurred within 30 days post-infusion in the 40 patients, regardless of whether the investigators attributed the events to the CAR T cell treatment.

\*GVHD assessment only included patients who relapsed after alloSCT and subsequently received donor-derived CD7 CAR-T therapy.

\*\*AEs after day 30 only applied to the 37 patients who achieved a response to CD7 CAR-T therapy and did not receive subsequent SCT. AEs recording was discontinued for patients who withdrew from the study after relapse. AEs were graded according to CTCAE v5.0.

Abbreviation: AE, adverse event; AlloSCT, allogeneic stem-cell transplantation; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CRS, cytokine release symptom; GVHD, graft-versus-host disease; ICANS, immune effector cell associated neurotoxicity syndrome; ICP, intracranial pressure; IEC-HS, Immune effector cell associated HLH-like syndrome; LDH, lactate Dehydrogenase.